

Docket No.: A7542.0000/P001-E

Application No.: 09/824,647 Amendment dated August 21, 2003 Reply to Office Action dated July 15, 2003

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Amendments To The Claims:

Claims 1-27 (cancelled).

- 28. (Previously presented) A composition comprising an isolated antibody capable of binding to an epitope of the protein encoded by SEQ ID NO: 16, wherein said antibody has anti-tumorigenic activity.
- 29. (Previously presented) A composition according to claim 28, wherein said antibody inhibits the growth of tumorigenic cells by at least about 50%.
- 30. (Previously presented) A composition according to claim 28, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.
- 31. (Previously presented) A composition according to claim 28, wherein said antibody is selected from a group consisting of anti-K19T, anti-S14R, anti-E19V, and anti-A14R antibodies.
- 32. (Previously presented) A composition according to claim 28, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 3.
- 33. (Previously presented) A composition according to claim 28, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 4.
- 34. (Previously presented) A composition according to claim 28, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 5.
- 35. (Previously presented) A composition according to claim 28, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 6.

Docket No.: A7542.0000/P001-E

- 36. (Previously presented) A composition according to claim 28, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 7.
- 37. (Previously presented) A composition according to claim 28, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 16.
- 38. (Previously presented) The composition of claim 28, wherein said antibody is a chimeric antibody comprising a plurality of portions, wherein at least one portion is derived from a human.
- 39. (Previously presented) The composition of claim 38, wherein at least one portion is derived from a non-human animal.
- 40. (Previously presented) The composition of claim 39, wherein said non-human animal is a mouse.
- 41. (Previously presented) The composition of claim 38, wherein said at least one portion is a constant region.
- 42. (Previously presented) The composition of claim 38, wherein said at least one portion is a variable region.
- 43. (Previously presented) The composition of claim 28, further comprising a cytotoxic molecule, wherein said antibody is attached to said cytotoxic molecule.
- 44. (Previously presented) The composition of claim 43, wherein said cytotoxic molecule is selected from the group consisting of toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides.
- 45. (Previously presented) The composition of claim 43, wherein said cytotoxic molecule is an oncotoxin.

Docket No.: A7542.0000/P001-E

- 46. (Previously presented) A composition comprising a monoclonal antibody capable of binding to an epitope of the protein encoded by SEQ ID NO: 16, wherein said monoclonal antibody has anti-tumorigenic activity.
- 47. (Previously presented) A composition according to claim 46, wherein said antibody inhibits the growth of tumorigenic cells by at least about 50%.
- 48. (Previously presented) A composition according to claim 46, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.
- 49. (Previously presented) A composition according to claim 46, wherein said antibody is selected from a group consisting of anti-K19T, anti-S14R, anti-E19V, and anti-A14R antibodies.

Claims 50-55 (Cancelled).

- 56. (Previously presented) A method of inhibiting tumorigenic activity, comprising obtaining an antibody capable of binding to an epitope of the protein encoded by SEQ ID NO: 16, wherein said antibody inhibits tumorigenic activity; and contacting said antibody with the protein encoded by SEQ ID NO: 16.
- 57. (Previously presented) A method according to claim 56, wherein said antibody is selected from the group consisting of anti-K19T, anti-S14R, anti-E19V, and anti-A14R antibodies.
- 58. (Previously presented) A method according to claim 56, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.
- 59. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 3.



Docket No.: A7542.0000/P001-E

- 60. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 4.
- 61. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 5.
- 62. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 6.
- 63. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 7.
- 64. (Previously presented) A method according to claim 56, wherein said antibody is isolated from an animal immunized with a material comprising SEQ ID NO: 16.
- 65. (Previously presented) A method of inhibiting tumor cell proliferation, comprising administering to a tumor cell an effective amount of an antibody capable of binding to an epitope encoded by SEQ ID NO: 16, wherein said antibody inhibits tumor cell proliferation.
- 66. (Previously presented) A method according to claim 65, wherein said tumor cell is selected from the group consisting of breast, ovarian, adipose, brain, liver, and kidney cells.
- 67. (Previously presented) A method according to claim 65, wherein said antibody inhibits tumor cell proliferation by at least about 50%.
- 68. (Previously presented) A method according to claim 65, wherein said antibody is selected from the group consisting of anti-K19T, anti-S14R, anti-E19V and anti-A14R antibodies.

Docket No.: A7542.0000/P001-E

- 69. (Previously presented) A method according to claim 65, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.
- 70. (Previously presented) A method according to claim 65, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 3.
- 71. (Previously presented) A method according to claim 65, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 4.
- 72. (Previously presented) A method according to claim 65, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 5.
- 73. (Previously presented) A method according to claim 65, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 6.
- 74. (Previously presented) A method according to claim 65, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 7.
- 75. (Previously presented) A method according to claim 65, wherein said antibody is produced in an animal immunized with a material comprising SEQ ID NO: 16.

